Search Results
Your search for all items matches 33289 pages
Showing 1 - 50FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma
On May 8, 2026, the U.S. Food and Drug Administration (FDA) approved the HER2- and HER3–directed bispecific antibody, zenocutuzumab-zbco (Bizengri), for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or...
I’m Young and Have Advanced Neuroendocrine Carcinoma of the Rectum
Eight years ago, I was 33 years old, and my main health concern was a diagnosis of ankylosing spondylitis, a form of arthritis that causes stiff, painful joints in the spine. Having a chronic disease made me pay close attention to any changes in my health, so when I noticed blood in my stool, I...
Patient Care Is Not What We Do, But What Patients Perceive
In modern health care, patient care is often defined by clinical actions such as diagnoses made, treatments delivered, and protocols followed. Clinicians are trained to prioritize technical accuracy, evidence-based interventions, and measurable outcomes. However, an equally critical and often...
Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book
ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book. Dr. Hsu is a Professor of Clinical Medicine at the University of California, San Francisco (UCSF), where he has served in numerous educational leadership roles. Since 2018,...
New ASCO Guideline Fills Gap in Guidance on Rapidly Evolving Treatment Options in Thyroid Cancer
ASCO has issued a new clinical practice guideline on the use of systemic therapy for treatment of different types of thyroid cancer, a field that has changed substantially in recent years.1 “Despite a rather rapidly evolving field of targeted and nontargeted systemic agents in the management of...
National Academy of Medicine Recognizes 100 Newly Elected Members
Overview of Member Election Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current members through a process that acknowledges individuals who have made major...
ARS Honors Thomas Buchholz, MD, With 2026 Gold Medal Award
The American Radium Society (ARS) presented its 2026 Gold Medal Award to Scripps Cancer Center Medical Director Thomas Buchholz, MD, at its Annual Meeting in Newport Beach, California. The Gold Medal Award is the organization’s highest honor for a member who has made significant contributions to...
From Hawaii to Health AI: A Career at the Intersection of Oncology, Data Science, and Clinical Knowledge
Raised in Lahaina, Hawaii, before wildfires destroyed much of the small tourist town in 2023, Travis Zack, MD, PhD, took an atypical path into medicine. His journey has been shaped by family, mentors, a personal experience with cancer, and a growing interest in how artificial intelligence (AI) can...
Could AI Be Licensed to Practice Oncology?
Is artificial intelligence (AI) poised to practice medicine? It may be already. Earlier this year, the state of Utah allowed Doctronic, a health technology company using AI to make clinical decisions autonomously, to renew prescriptions for patients who request the service. Although Utah’s pilot...
Long-Term Risks Revealed for Older Survivors of Childhood Cancers
Survivors of childhood cancer who reach the age of 50 and beyond show continued elevated risks for premature mortality, subsequent cancers, and other chronic health conditions, according to a report published in the Journal of Clinical Oncology.1 When compared with the general population or sibling ...
Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures
Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occurring in low- and middle-income countries.1 Delays in obtaining an accurate diagnosis,...
Can Physical Activity Reduce Cancer-Related Fatigue?
Greater physical activity—particularly walking—may reduce fatigue and improve quality of life in patients with colorectal cancer, with stronger associations observed in nonmetastatic disease. These findings were demonstrated in a longitudinal analysis of the ColoCare Study population presented by...
LLM-Based Preoperative Patient Communications Alleviate Anxiety, Physician Workload
Researchers from the Department of Urology at Fudan University Shanghai Cancer Center evaluated artificial intelligence (AI)–assisted communications in the preoperative setting to assess its impact on patient anxiety and clinician workload. The performance of the model was assessed in a...
LLM Tool Significantly Reduces Participant Screening Burdens, Improves Enrollment for Phase III Trial in Polycythemia Vera
Synapsis AI, a medically trained, large language model (LLM)–based end-to-end system, reduced the time and effort needed to screen for eligible patients to participate in a randomized, interventional phase III clinical trial in patients with polycythemia vera (PV). Use of Synapsis AI also led to...
De-escalation, Recovery, and Robotic Surgery in Breast Cancer Care
At the American Society of Breast Surgeons (ASBrS) 27th Annual Meeting, investigators presented new findings on breast cancer surgery, postoperative recovery, and radiation treatment planning. Among the many sessions, several studies were presented during a media briefing earlier this month and are ...
Tiragolumab/Atezolizumab and Chemotherapy Fails in Advanced Nonsquamous NSCLC
As reported in JAMA Oncology by Socinski et al, the phase III SKYSCRAPER-06 trial showed no progression-free or overall survival benefit with tiragolumab, a monoclonal antibody targeting T-cell immunoreceptor with Ig and ITIM domains (immunoreceptor tyrosine-based inhibitory motifs) (TIGIT), plus...
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
In an analysis of a single-center trial reported in a research letter in JAMA Oncology, Reiss et al identified long-term outcomes with rucaparib maintenance in patients with platinum-sensitive advanced pancreatic ductal adenocarcinoma (PDAC) with BRCA1, BRCA2, or PALB2 germline or somatic...
Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing Cytoreductive Surgery
A retrospective study found that levels of commonly measured serum tumor markers—CEA, CA19-9, and CA125—can play a significant role in predicting outcomes in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery (CRS), with or without hyperthermic intraperitoneal chemotherapy...
High YAP1 Expression Leads to Chemotherapy Resistance, Relapse in Treated SCLC
Expression of the YAP1 protein following treatment with chemotherapy is associated with the development of treatment resistance and cancer relapse in patients with small cell lung cancer (SCLC), according to findings from an analysis published in Journal of Thoracic Oncology. The researchers...
AI Pathology Framework for Biological Understanding of Tumors
An agentic artificial intelligence (AI) framework may help researchers gain a better understanding of hidden biological information of tumors, according to a study published in Nature Medicine. “SPARK helps to refine diagnoses, stratify patients more reliably, and make more precise treatment...
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alone. Interim results from the CLIMATE study found post-orchiectomy plasma miR-371a-3p (miR-371), a...
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer improves patient outcomes. Clinicians should therefore proceed with caution until such evidence...
Breast Density Reduction: Endoxifen vs Tamoxifen
Low doses of the investigational agent endoxifen reduced breast density to the same extent as the standard treatment tamoxifen, with fewer adverse events, according to results from the KARISMA study, a proof-of-principle, dose-determining, double-blinded, randomized, placebo-controlled trial. These ...
AI Model Enables Earlier Detection of Pancreatic Cancer on Routine CT Scans
In a landmark study published in Gut, Mukherjee et al developed and validated the Radiomics-based Early Detection Model (REDMOD), an automated artificial intelligence (AI) framework that identifies subtle, preclinical imaging signatures of pancreatic ductal adenocarcinoma on routine computed...
Advanced CKM Syndrome Associated With Greater Cancer Risk
Advanced cardiovascular-kidney-metabolic (CKM) syndrome may be associated with an increased risk of developing cancer, according to findings from a Japanese study published in Circulation: Population Health and Outcomes. “The study findings suggest that it is important to consider not only...
Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL
In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL). Study Details The analysis included clinical and molecular data from 3,091 individuals which was derived from...
Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases
In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intravenous (IV) oxaliplatin, both combined with fluorouracil/leucovorin (LV5FU2), after curative-intent...
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
Investigators used data from the Surveillance, Epidemiology, and End Results (SEER) database to analyze trends in multiple myeloma mortality in the United States from 1975 to 2023. Their findings were published in Oncotarget. The study was led by first and corresponding author Navkirat Kahlon, MD,...
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) had longer survival compared to national benchmarks when treated in independent community oncology practices, according to a new study commissioned by the Community Oncology Alliance (COA) and conducted by...
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
On May 1, the U.S. Food and Drug Administration announced that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib. In mid-April, Revolution Medicines...
Four-Drug Regimen Induces High Complete Response Rate in Early-Stage Classical Hodgkin Lymphoma
High objective response and complete response rates were observed with treatment with brentuximab vedotin and nivolumab in combination with doxorubicin and dacarbazine chemotherapy in patients with early-stage classical Hodgkin lymphoma, according to the results of a phase II trial published in...
On-Treatment PSA and Overall Survival in Prostate Cancer
In a post hoc analysis reported in The Lancet Oncology, Kayani et al found that on-treatment prostate-specific antigen (PSA) level was associated with overall survival in patients with metastatic or very high-risk nonmetastatic prostate adenocarcinoma from five phase III trials in the STAMPEDE...
FDA Approves Vepdegestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer
On May 1, the U.S. Food and Drug Administration (FDA) approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized ...
Association of Body Size and Bladder Cancer Risk
In a study—The Pooling Project of Prospective Studies of Diet and Cancer—reported in the Journal of Clinical Oncology, Milne et al in the National Cancer Institute Cohort Consortium found that increased body size is associated with increased risk of bladder cancer among men, but not among women....
Can PFAS Exposure Raise ALL Risk?
Early exposure to per- and polyfluoroalkyl substances (PFAS), a group of widely used compounds known as “forever chemicals,” may be associated with a higher risk of developing acute lymphoblastic leukemia (ALL), according to findings published by Vieira et al in the Journal of Exposure Science...
Melanoma: Gut Microbiome May Help Predict Recurrence After Immunotherapy
Gut bacterial markers may be able to predict recurrence in patients with high-risk melanoma receiving adjuvant immune checkpoint inhibition, according to study findings published in Cell. “Our study identified for the first time gut bacterial types that can serve as markers of increased recurrence ...
Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up From AUGMENT
As reported in the Journal of Clinical Oncology by Leonard et al, the 5-year follow-up of the phase III AUGMENT trial has shown continued benefit of lenalidomide plus rituximab (R2) vs rituximab with placebo (R-placebo) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Study...
Atezolizumab in Alveolar Soft Part Sarcoma: Long-Term Follow-up
As reported in the Journal of Clinical Oncology by Chen et al, extended follow-up of the pivotal phase II trial of atezolizumab in patients with alveolar soft part sarcoma (ASPS) showed continued benefit of atezolizumab treatment. Study Details In the U.S. multicenter trial, 53 patients received...
Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib improved progression-free survival, produced a higher objective response rate, and showed a trend...
Acupuncture for Nocturia in Survivors of Prostate Cancer
Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality than the general population. The evidence supporting current treatment options for nocturia is weak. ...
Can Pesticide Exposure Increase Early-Onset Colorectal Cancer Risk?
A new study has identified for the first time the exposome footprint—the set of environmental and lifestyle exposures—for colorectal cancer occurring in patients younger than age 50 through epigenetic signatures. By comparatively analyzing DNA methylation patterns in patients under and over 50, the ...
Metabolic Tumor Volume Predicts CAR T-Cell Therapy Response in LBCL
Positron-emission tomography (PET)-based metabolic tumor volume could serve as a significant measure of response to chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma, according to the results of a study published in The Journal of Nuclear Medicine. Metabolic...
MIBC: Pembrolizumab With Trimodal Therapy for Bladder Preservation
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy and maximal transurethral resection may be safe and feasible in patients with muscle-invasive bladder cancer (MIBC), allowing many patients to potentially avoid cystectomy, according to the results of a...
AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS
Monitoring for relapse with an artificial intelligence (AI)-powered peripheral blood-based tool called AlloHeme demonstrated greater sensitivity in predicting relapse after hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) than ...
Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC
As reported in the Journal of Clinical Oncology by Li et al, long-term follow-up of a Chinese phase II trial (TRUST-I) showed prolonged activity with taletrectinib in patients with ROS1 mutation–positive non–small cell lung cancer (NSCLC). Study Details In the multicenter trial, 173 patients had...
Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer
In a phase Ib/II study (OrigAMI-1) reported in the Journal of Clinical Oncology, Oberstein et al found that the EGFR-MET bispecific antibody amivantamab-vmjw showed activity when used as monotherapy in patients with chemorefractory RAS/BRAF wild-type metastatic colorectal cancer. Study Details In...
Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age
Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen (PSA) screening is low in younger men—but rises sharply with age. The study, which aimed to estimate the impact of age on overdiagnosis of prostate cancer 15 years after screening stops, analyzed...
Tracking Biological Age Changes Gives Insights Into Cancer Prognosis
Face aging rate, a measure of changes in biological age over time, could serve as a noninvasive prognostic biomarker for determining outcomes in patients with cancer, according to the results of a study published in Nature Communications. “Deriving a Face Aging Rate from multiple, routine facial...
Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality
Long-term exposure to air pollution significantly increases both the risk of developing cancer and the likelihood of dying from the disease, according to a new global evidence report released by the Union for International Cancer Control (UICC), titled Clean air in cancer control: An overview of...
Do Political Beliefs Shape Views on Clinical Trials in Cancer?
In a cross-sectional study published in JAMA Network Open, political ideology was associated with clinical trial skepticism, with conservative identification linked to higher odds of endorsing such views. Among cancer survivors, Chido-Amajuoyi et al similarly observed greater skepticism among...
